Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS North America Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Preview AMS TV
Features
AMS Features
News & Publications
AMS Bookstore
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial
By
- AMS
posted
Sep 25, 2020 07:09 AM
0
Recommend
.
0 comments
1 view
Permalink
Related Content
Cognitive behavioral therapy as an adjuvant therapy in acne excoriée: a randomized controlled clinical trial
- AMS
Added Jun 12, 2020
Blog Entry
Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies
- AMS
Added May 03, 2021
Blog Entry
Improving hidradenitis suppurativa patient education using written action plan: a randomized controlled trial
- AMS
Added Sep 28, 2021
Blog Entry
A split-face randomized controlled trial of treatment with broadband light for enlarged facial pores
- AMS
Added Dec 05, 2019
Blog Entry
Successful treatment of the face post acne erythema using a topically applied selective alpha 1-Adrenergic receptor agonist, oxymetazoline 1.5%, a controlled left to right face comparative trial
- AMS
Added Jul 07, 2020
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic